These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

953 related items for PubMed ID: 23071247

  • 1. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.
    Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Curran W, Mehta M.
    J Clin Oncol; 2013 Jan 20; 31(3):337-43. PubMed ID: 23071247
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.
    van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Enting RH, French PJ, Dinjens WN, Vecht CJ, Allgeier A, Lacombe D, Gorlia T, Hoang-Xuan K.
    J Clin Oncol; 2013 Jan 20; 31(3):344-50. PubMed ID: 23071237
    [Abstract] [Full Text] [Related]

  • 4. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.
    Cairncross JG, Wang M, Jenkins RB, Shaw EG, Giannini C, Brachman DG, Buckner JC, Fink KL, Souhami L, Laperriere NJ, Huse JT, Mehta MP, Curran WJ.
    J Clin Oncol; 2014 Mar 10; 32(8):783-90. PubMed ID: 24516018
    [Abstract] [Full Text] [Related]

  • 5. Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide.
    Speirs CK, Simpson JR, Robinson CG, DeWees TA, Tran DD, Linette G, Chicoine MR, Dacey RG, Rich KM, Dowling JL, Leuthardt EC, Zipfel GJ, Kim AH, Huang J.
    Int J Radiat Oncol Biol Phys; 2015 Feb 01; 91(2):268-76. PubMed ID: 25636755
    [Abstract] [Full Text] [Related]

  • 6. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies.
    Roth P, Wick W, Weller M.
    Curr Treat Options Oncol; 2013 Dec 01; 14(4):505-13. PubMed ID: 23907441
    [Abstract] [Full Text] [Related]

  • 7. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.
    van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D, Gorlia T.
    J Clin Oncol; 2006 Jun 20; 24(18):2715-22. PubMed ID: 16782911
    [Abstract] [Full Text] [Related]

  • 8. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
    Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M.
    J Clin Oncol; 2009 Dec 10; 27(35):5874-80. PubMed ID: 19901110
    [Abstract] [Full Text] [Related]

  • 9. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402.
    Giannini C, Burger PC, Berkey BA, Cairncross JG, Jenkins RB, Mehta M, Curran WJ, Aldape K.
    Brain Pathol; 2008 Jul 10; 18(3):360-9. PubMed ID: 18371182
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and prognostic value of molecular markers.
    Minniti G, Arcella A, Scaringi C, Lanzetta G, Di Stefano D, Scarpino S, Pace A, Giangaspero F, Osti MF, Enrici RM.
    J Neurooncol; 2014 Jan 10; 116(2):275-82. PubMed ID: 24162810
    [Abstract] [Full Text] [Related]

  • 12. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802.
    Shaw EG, Wang M, Coons SW, Brachman DG, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR, Mehta MP.
    J Clin Oncol; 2012 Sep 01; 30(25):3065-70. PubMed ID: 22851558
    [Abstract] [Full Text] [Related]

  • 13. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.
    van den Bent MJ, Dubbink HJ, Sanson M, van der Lee-Haarloo CR, Hegi M, Jeuken JW, Ibdaih A, Brandes AA, Taphoorn MJ, Frenay M, Lacombe D, Gorlia T, Dinjens WN, Kros JM.
    J Clin Oncol; 2009 Dec 10; 27(35):5881-6. PubMed ID: 19901104
    [Abstract] [Full Text] [Related]

  • 14. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.
    Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, DeAngelis LM, Jhanwar SC, Rosenblum MK, Panageas KS.
    Neuro Oncol; 2011 Jun 10; 13(6):649-59. PubMed ID: 21636710
    [Abstract] [Full Text] [Related]

  • 15. How to use molecular markers when caring for a patient with brain cancer: 1P/19Q as a predictive and prognostic marker in the neuro-oncology clinic.
    van den Bent MJ.
    Am Soc Clin Oncol Educ Book; 2013 Jun 10; ():114-6. PubMed ID: 23714473
    [Abstract] [Full Text] [Related]

  • 16. Co-deletion of 1p/19q as Prognostic and Predictive Biomarker for Patients in West Bohemia with Anaplastic Oligodendroglioma.
    Polivka J, Polivka J, Repik T, Rohan V, Hes O, Topolcan O.
    Anticancer Res; 2016 Jan 10; 36(1):471-6. PubMed ID: 26722084
    [Abstract] [Full Text] [Related]

  • 17. Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
    McDuff SGR, Dietrich J, Atkins KM, Oh KS, Loeffler JS, Shih HA.
    Cancer Med; 2020 Jan 10; 9(1):3-11. PubMed ID: 31701682
    [Abstract] [Full Text] [Related]

  • 18. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.
    Kouwenhoven MC, Gorlia T, Kros JM, Ibdaih A, Brandes AA, Bromberg JE, Mokhtari K, van Duinen SG, Teepen JL, Wesseling P, Vandenbos F, Grisold W, Sipos L, Mirimanoff R, Vecht CJ, Allgeier A, Lacombe D, van den Bent MJ.
    Neuro Oncol; 2009 Dec 10; 11(6):737-46. PubMed ID: 19224764
    [Abstract] [Full Text] [Related]

  • 19. Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma.
    Bell EH, Zhang P, Shaw EG, Buckner JC, Barger GR, Bullard DE, Mehta MP, Gilbert MR, Brown PD, Stelzer KJ, McElroy JP, Fleming JL, Timmers CD, Becker AP, Salavaggione AL, Liu Z, Aldape K, Brachman DG, Gertler SZ, Murtha AD, Schultz CJ, Johnson D, Laack NN, Hunter GK, Crocker IR, Won M, Chakravarti A.
    J Clin Oncol; 2020 Oct 10; 38(29):3407-3417. PubMed ID: 32706640
    [Abstract] [Full Text] [Related]

  • 20. Initial treatment patterns over time for anaplastic oligodendroglial tumors.
    Panageas KS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán Urgoiti GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, Deangelis LM, Jhanwar SC, Rosenblum MK, Lassman AB.
    Neuro Oncol; 2012 Jun 10; 14(6):761-7. PubMed ID: 22661585
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.